Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULYSSES: Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
NCT05933057Phase 3Recruiting
- Sponsor
- Italfarmaco
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Givinostat with Placebo (2 arms). Primary endpoint: Change of Performance of Upper Limb 2.0 (PUL) total score at 18 months. Started Feb 2024; status: recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05933057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933057.